Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Third party research

Vitrolife: Analyst - ABG

Vitrolife

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
Q4'23 results due 2 February
23e EBITDA cut 1.4% and down 11.5% & 12.8% for '24e & '25e
38-45% below historical multiples, but above sector peers


Q4'23 expectations

We expect Vitrolife to report organic sales growth of 2.8%, broadly in line with what it reported in Q2'23 and Q3'23. We expect the Genetic service business in Americas to hold back total sales growth again in Q4, primarily due to the issues with the ERA test in the US. However, we expect positive growth for the other product categories and regions in Q4. We forecast Q4 EBITDA of SEK 289.5m, for a margin of 32.8%, up from 32.0% in Q4 '22 because of good cost control and a higher reported gross margin, 55.5% vs. 54.1% in Q4'22.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.